Developer docs
API playgroundTry for free, no card

Search company profiles

EarliTec Diagnostics

Full company profile

uuid0000mor

Namestring
EarliTec Diagnostics
Legal namestring
Earlitec Diagnostics dba EarliPoint Health®, Inc
Websiteurl
earlitecdx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

EarliTec Diagnostics, operating as EarliPoint Health, Inc., is a Plymouth, Minnesota-based healthcare technology company founded in 2019 that develops FDA-cleared eye-tracking diagnostic tools for Autism Spectrum Disorder. Its core product, the EarliPoint System, is a portable-tablet medical device that records where and how long a child watches social and non-social video scenes. Proprietary algorithms analyze these visual-attention patterns as biometric markers, generating scores across three clinically aligned indices (language, cognition, and social engagement) to aid qualified clinicians in diagnosing and assessing ASD in children aged 16 to 95 months. The system was the first FDA-authorized objective autism assessment tool for children as young as 16 months and is validated through two large-scale, double-blind clinical studies published in JAMA, with research conducted in collaboration with Yale University and Emory University.

The company sells the EarliPoint System exclusively to healthcare providers and autism care networks through enterprise field sales, supported by a "Request A Demo" funnel and an EarliPoint Network provider directory that includes a low-cost access program. Pricing is quote-based and not publicly disclosed; customers typically enter multi-year arrangements and deploy devices in clinical settings including pediatric hospitals (e.g., Nicklaus Children's, Cincinnati Children's), autism centers (Marcus Autism Center, SARRC, Cortica), regional health systems (St. Charles Health System), and community providers (Easterseals Florida). In June 2026, EarliPoint launched Skill Illustrator, an add-on that translates assessment data into actionable developmental insights, extending the platform from initial diagnosis into treatment-progress tracking and outcome measurement.

EarliTec has raised approximately $44.5 million across three financing rounds, including a $19.5 million round in February 2022 led by Bernie Marcus and the Georgia Research Alliance, a $21.5 million round in April 2024 led by Nexus NeuroTech and Clarevia Ventures, and a $3.5 million tranche in April 2026. The company is led by President and CEO Jamie Pagliaro and Chief Clinical Officer and Co-Founder Dr. Ami Klin, Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine. The company employs 11-50 people and operates exclusively in the United States.

Short descriptiontext

EarliTec Diagnostics (dba EarliPoint Health) develops and sells an FDA-cleared, eye-tracking-based diagnostic system that helps clinicians objectively assess Autism Spectrum Disorder in children aged 16 to 95 months, selling exclusively to U.S. healthcare providers and autism care networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autism diagnostic device, eye tracking assessment, FDA-cleared medical device, autism spectrum disorder, visual attention biomarkers
Industry1 code
PRIMARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Autism Diagnostic Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1EarliPoint System Device and Assessment Services
TypeHardware Sales
Description

FDA-cleared medical device system for clinical use. The device is indicated as a tool to aid qualified clinicians in diagnosis and assessment of ASD. Healthcare providers (clinics, hospitals, autism centers) purchase access to the EarliPoint system for use in their practices.

earlipointhealth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Clinical use pricing for healthcare providers
ModelOtherBilling cadenceMulti-year contract
Notes

Not for direct consumer purchase; clinician use only. Quote-based pricing for healthcare providers and autism care networks.

earlipointhealth.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1EarliPoint System
Description

FDA-cleared eye-tracking technology using visual attention biomarkers for autism diagnosis, indicated for children ages 16 months through 95 months.

earlipointhealth.com
+3 more records
Core offering1 text field

EarliTec Diagnostics, operating as EarliPoint Health, sells the FDA-cleared EarliPoint System — a portable eye-tracking medical device that captures where and how long a child watches video scenes. Proprietary algorithms convert that gaze data into objective scores across language, cognition, and social engagement indices to aid clinicians in diagnosing and assessing Autism Spectrum Disorder in children ages 16 to 95 months. The system is sold to healthcare providers, hospitals, autism centers, and clinical networks for in-practice use, not directly to consumers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Enables autism diagnosis as early as 16 months (vs. average U.S. diagnosis age of 4+ years)
+2 more records
Product overview1 text field

EarliTec Diagnostics (dba EarliPoint Health) offers the EarliPoint® System as its core product—an FDA-cleared eye-tracking diagnostic aid for Autism Spectrum Disorder. The system consists of a portable tablet device that captures eye gaze data while children watch video scenes, proprietary algorithms that analyze visual-attention patterns, and detailed reporting across three clinically aligned indices (language, cognition, social engagement). The Skill Illustrator™ module extends the platform by translating assessment data into actionable developmental insights for clinicians and families.

Product and service1 record
1EarliPoint System
CategoryAutism Diagnostic Medical Device
Description

FDA-cleared medical device using portable tablet-based eye-tracking to measure how children visually engage with social and non-social video scenes, producing objective reports with scores across language, cognition, and social engagement indices to aid clinicians in diagnosing and assessing Autism Spectrum Disorder in children ages 16 to 95 months. Sold to healthcare providers, hospitals, autism centers, and clinical networks; not available for direct consumer purchase.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-05
Description

Academic research partner in the development of EarliPoint System. Research conducted in collaboration with Yale University contributed to JAMA-published clinical validation studies on eye-tracking-based measurement of social visual engagement for autism diagnosis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Ami Klin serves as Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine. Emory-affiliated Marcus Autism Center is a key research and clinical partner. Research collaboration contributed to FDA-cleared EarliPoint System development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Cognoa is the most direct competitor: an AI-driven, FDA-authorized diagnostic for autism spectrum disorder (Canvas Dx) targeting young children. Both companies are pursuing the same objective, early, device/software-enabled autism diagnosis use case for pediatric populations via enterprise health channels.

TypeBroad incumbent
Description

Pearson publishes and distributes the ADOS-2 and ADI-R — the gold-standard clinician-administered behavioral autism assessments that EarliPoint is positioned to complement and partially displace. Comparable as the incumbent benchmark that defines the existing autism diagnostic workflow EarliTec targets.

TypeBroad incumbent
Description

WPS publishes the CARS-2 (Childhood Autism Rating Scale), another widely used behavioral autism diagnostic tool in clinical practice. As a publisher and distributor of established autism assessment instruments, WPS represents the legacy assessment ecosystem EarliTec's device-based modality must penetrate.

TypeBroad incumbent
Description

Tobii is the leading global eye-tracking technology platform with applications across healthcare, research, and consumer devices. Comparable as both a potential component supplier/partner for EarliTec's hardware and a broader incumbent whose technology could be deployed into autism and developmental diagnostics.

TypeDirect peer
Description

RightEye develops eye-tracking-based clinical assessment tools for neurological and developmental conditions, sold to healthcare providers. Directly comparable as a company commercializing eye-tracking-based diagnostic and screening devices into clinical workflows analogous to EarliTec's go-to-market.

TypeEmerging player
Description

Qbtech develops FDA-cleared, objective digital diagnostic tools (QbTest) for ADHD using sensor-based measurement of attention and activity. Comparable business model and regulatory pathway to EarliTec — device-based, objective, FDA-cleared adjunct diagnostics for developmental conditions sold to clinicians.

TypeEmerging player
Description

Behavior Imaging Solutions provides video-based remote behavioral observation and assessment tools used in autism diagnosis and treatment planning. Comparable as an emerging technology-enabled autism assessment company targeting the same provider ecosystem, though with a video-based rather than eye-tracking approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EarliTec Diagnostics

Autism Diagnostic Medical Devicesearlitecdx.com

EarliTec Diagnostics (dba EarliPoint Health) develops and sells an FDA-cleared, eye-tracking-based diagnostic system that helps clinicians objectively assess Autism Spectrum Disorder in children aged 16 to 95 months, selling exclusively to U.S. healthcare providers and autism care networks.

What EarliTec Diagnostics does

EarliTec Diagnostics, operating as EarliPoint Health, Inc., is a Plymouth, Minnesota-based healthcare technology company founded in 2019 that develops FDA-cleared eye-tracking diagnostic tools for Autism Spectrum Disorder. Its core product, the EarliPoint System, is a portable-tablet medical device that records where and how long a child watches social and non-social video scenes. Proprietary algorithms analyze these visual-attention patterns as biometric markers, generating scores across three clinically aligned indices (language, cognition, and social engagement) to aid qualified clinicians in diagnosing and assessing ASD in children aged 16 to 95 months. The system was the first FDA-authorized objective autism assessment tool for children as young as 16 months and is validated through two large-scale, double-blind clinical studies published in JAMA, with research conducted in collaboration with Yale University and Emory University.

The company sells the EarliPoint System exclusively to healthcare providers and autism care networks through enterprise field sales, supported by a "Request A Demo" funnel and an EarliPoint Network provider directory that includes a low-cost access program. Pricing is quote-based and not publicly disclosed; customers typically enter multi-year arrangements and deploy devices in clinical settings including pediatric hospitals (e.g., Nicklaus Children's, Cincinnati Children's), autism centers (Marcus Autism Center, SARRC, Cortica), regional health systems (St. Charles Health System), and community providers (Easterseals Florida). In June 2026, EarliPoint launched Skill Illustrator, an add-on that translates assessment data into actionable developmental insights, extending the platform from initial diagnosis into treatment-progress tracking and outcome measurement.

EarliTec has raised approximately $44.5 million across three financing rounds, including a $19.5 million round in February 2022 led by Bernie Marcus and the Georgia Research Alliance, a $21.5 million round in April 2024 led by Nexus NeuroTech and Clarevia Ventures, and a $3.5 million tranche in April 2026. The company is led by President and CEO Jamie Pagliaro and Chief Clinical Officer and Co-Founder Dr. Ami Klin, Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine. The company employs 11-50 people and operates exclusively in the United States.

EarliTec Diagnostics firmographics

Firmographics
Name
EarliTec Diagnostics
Legal name
Earlitec Diagnostics dba EarliPoint Health®, Inc
Website
https://earlitecdx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
EarliTec Diagnostics (dba EarliPoint Health) develops and sells an FDA-cleared, eye-tracking-based diagnostic system that helps clinicians objectively assess Autism Spectrum Disorder in children aged 16 to 95 months, selling exclusively to U.S. healthcare providers and autism care networks.
Ownership category
akta.pro rank

EarliTec Diagnostics industry classification

Industry
Product category
Autism Diagnostic Medical Devices
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)

Keywords

  • Autism diagnostic device
  • Eye tracking assessment
  • FDA-cleared medical device
  • Autism spectrum disorder
  • Visual attention biomarkers

Where EarliTec Diagnostics is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EarliTec Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. EarliPoint System Device and Assessment Services: FDA-cleared medical device system for clinical use. The device is indicated as a tool to aid qualified clinicians in diagnosis and assessment of ASD. Healthcare providers (clinics, hospitals, autism centers) purchase access to the EarliPoint system for use in their practices.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractClinical use pricing for healthcare providers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

EarliTec Diagnostics product offering

Product offering

Core offering

EarliTec Diagnostics, operating as EarliPoint Health, sells the FDA-cleared EarliPoint System — a portable eye-tracking medical device that captures where and how long a child watches video scenes. Proprietary algorithms convert that gaze data into objective scores across language, cognition, and social engagement indices to aid clinicians in diagnosing and assessing Autism Spectrum Disorder in children ages 16 to 95 months. The system is sold to healthcare providers, hospitals, autism centers, and clinical networks for in-practice use, not directly to consumers.

Product overview

EarliTec Diagnostics (dba EarliPoint Health) offers the EarliPoint® System as its core product—an FDA-cleared eye-tracking diagnostic aid for Autism Spectrum Disorder. The system consists of a portable tablet device that captures eye gaze data while children watch video scenes, proprietary algorithms that analyze visual-attention patterns, and detailed reporting across three clinically aligned indices (language, cognition, social engagement). The Skill Illustrator™ module extends the platform by translating assessment data into actionable developmental insights for clinicians and families.

Differentiator

Problem solved

Functional benefit

Brands

  • EarliPoint System: FDA-cleared eye-tracking technology using visual attention biomarkers for autism diagnosis, indicated for children ages 16 months through 95 months.
  • EarliPoint Evaluation
  • Skill Illustrator
  • EarliPoint Network

Products and services

  • EarliPoint System FDA-cleared medical device using portable tablet-based eye-tracking to measure how children visually engage with social and non-social video scenes, producing objective reports with scores across language, cognition, and social engagement indices to aid clinicians in diagnosing and assessing Autism Spectrum Disorder in children ages 16 to 95 months. Sold to healthcare providers, hospitals, autism centers, and clinical networks; not available for direct consumer purchase.

Quantifiable outcome

  • Enables autism diagnosis as early as 16 months (vs. average U.S. diagnosis age of 4+ years)
  • +2 more outcomes

Companies that use EarliTec Diagnostics

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles1 record

EarliTec Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

EarliTec Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Yale UniversitycoreStrategic or Co-development Partner · 5 September 2019Academic research partner in the development of EarliPoint System. Research conducted in collaboration with Yale University contributed to JAMA-published clinical validation studies on eye-tracking-based measurement of social visual engagement for autism diagnosis.
  • Emory UniversitycoreStrategic or Co-development PartnerDr. Ami Klin serves as Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine. Emory-affiliated Marcus Autism Center is a key research and clinical partner. Research collaboration contributed to FDA-cleared EarliPoint System development.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

EarliTec Diagnostics competitors and assessment

Company assessment

Direct peers

  • Cognoa: Cognoa is the most direct competitor: an AI-driven, FDA-authorized diagnostic for autism spectrum disorder (Canvas Dx) targeting young children. Both companies are pursuing the same objective, early, device/software-enabled autism diagnosis use case for pediatric populations via enterprise health channels.
  • RightEye: RightEye develops eye-tracking-based clinical assessment tools for neurological and developmental conditions, sold to healthcare providers. Directly comparable as a company commercializing eye-tracking-based diagnostic and screening devices into clinical workflows analogous to EarliTec's go-to-market.

Broad incumbents

  • Pearson Clinical Assessment: Pearson publishes and distributes the ADOS-2 and ADI-R — the gold-standard clinician-administered behavioral autism assessments that EarliPoint is positioned to complement and partially displace. Comparable as the incumbent benchmark that defines the existing autism diagnostic workflow EarliTec targets.
  • Western Psychological Services (WPS): WPS publishes the CARS-2 (Childhood Autism Rating Scale), another widely used behavioral autism diagnostic tool in clinical practice. As a publisher and distributor of established autism assessment instruments, WPS represents the legacy assessment ecosystem EarliTec's device-based modality must penetrate.
  • Tobii: Tobii is the leading global eye-tracking technology platform with applications across healthcare, research, and consumer devices. Comparable as both a potential component supplier/partner for EarliTec's hardware and a broader incumbent whose technology could be deployed into autism and developmental diagnostics.

Emerging players

  • Qbtech: Qbtech develops FDA-cleared, objective digital diagnostic tools (QbTest) for ADHD using sensor-based measurement of attention and activity. Comparable business model and regulatory pathway to EarliTec — device-based, objective, FDA-cleared adjunct diagnostics for developmental conditions sold to clinicians.
  • Behavior Imaging Solutions: Behavior Imaging Solutions provides video-based remote behavioral observation and assessment tools used in autism diagnosis and treatment planning. Comparable as an emerging technology-enabled autism assessment company targeting the same provider ecosystem, though with a video-based rather than eye-tracking approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EarliTec Diagnostics social profiles

Digital presence

EarliTec Diagnostics compliance and trust

Trust signal

Compliance1 record

EarliTec Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EarliTec Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

EarliTec Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EarliTec Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EarliTec Diagnostics

What does EarliTec Diagnostics do?

EarliTec Diagnostics, operating as EarliPoint Health, sells the FDA-cleared EarliPoint System — a portable eye-tracking medical device that captures where and how long a child watches video scenes. Proprietary algorithms convert that gaze data into objective scores across language, cognition, and social engagement indices to aid clinicians in diagnosing and assessing Autism Spectrum Disorder in children ages 16 to 95 months. The system is sold to healthcare providers, hospitals, autism centers, and clinical networks for in-practice use, not directly to consumers.

Is EarliTec Diagnostics a public or private company?

EarliTec Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was EarliTec Diagnostics founded?

EarliTec Diagnostics was founded in 2019. It employs 11 to 50 people.

Where is EarliTec Diagnostics based?

EarliTec Diagnostics is headquartered in Atlanta, United States, in the North America region.

How does EarliTec Diagnostics make money?

One revenue line is on record: earliPoint System Device and Assessment Services.

Who are EarliTec Diagnostics's main competitors?

Direct peers on record are Cognoa and RightEye. Broad incumbents are Pearson Clinical Assessment, Western Psychological Services (WPS) and Tobii. Emerging players are Qbtech and Behavior Imaging Solutions.

Does EarliTec Diagnostics have an API?

No public API is recorded for EarliTec Diagnostics.

What industry is EarliTec Diagnostics in?

EarliTec Diagnostics's product category is Autism Diagnostic Medical Devices. Its primary akta.pro industry code is EDAKAKAA, Autism Diagnostic & Educational Assessment Services. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileEarliPoint Health and Zest Pediatric Network Partner to Expand Access to Autism Evaluations and Eliminate Diagnostic Wait TimesEarliPoint Health and Zest Pediatric Network announced a partnership to expand access to autism evaluations and reduce wait times. The collaboration lets providers offer diagnostic testing virtually, with results reviewed by Zest pediatricians at reduced cost. The goal is to scale evaluation locations nationwide and eliminate waitlists.GlobeNewswireHopebridge Partners with EarliTec Dx to Provide Objective Autism Assessment for Children up to Age 30 MonthsHopebridge partnered with EarliTec Diagnostics to use EarliPoint, an FDA-authorized eye-tracking device, for autism assessments in children aged 16-30 months. The pilot in Suwanee, GA, found EarliPoint correctly identifies autism in four out of five children. Hopebridge plans to expand the technology's impact beyond its centers.Pulse 2.0EarliTec Diagnostics: $21.5 Million Secured To Develop Therapeutic Solutions For Children With AutismEarliTec Diagnostics raised $21.5 million in Series B funding led by Nexus NeuroTech Ventures and Venture Investors Health Fund. The funds will expand commercialization and clinical research for EarliPoint, a first-in-kind diagnostic tool for children aged 16-30 months. The company plans to complete studies evaluating EarliPoint through age 7.TechCrunchDeal Dive: EarliTec Diagnostics raises $21.5M to help diagnose autism earlierEarliTec Diagnostics raised $21.5 million in a Series B round co-led by Nexus NeuroTech Ventures and Venture Investors. The Atlanta-based startup's FDA-authorized system uses AI to track eye movements during a 12-minute video test for children aged 16-30 months. The company plans to use the funds to expand commercialization and research to broaden the age range.Mpo-magEarliTec Diagnostics Raises $21.5M in Series B FinancingEarliTec Diagnostics raised $21.5 million in a Series B round led by Nexus Neuro Tech Ventures and Venture Investors Health Fund. The funding will support commercialization and clinical research for EarliPoint, a device for autism diagnosis in children 16-30 months old, which has FDA clearance and Georgia Medicaid coverage.EarlitecdxEarliTec Diagnostics, Inc. Raises $21.5 Million in Series B Financing; Funds to Accelerate Commercialization of EarliPoint Evaluation and Further Product DevelopmentEarliTec Diagnostics raised $21.5 million in a Series B round led by Nexus NeuroTech Ventures and Venture Investors Health Fund. The funds will accelerate commercialization of EarliPoint, a first-in-kind autism diagnostic tool for toddlers, and advance clinical research. Georgia Medicaid has included EarliPoint in its medical policy.Business Wire BlogEarliTec Diagnostics, Inc. Raises $21.5 Million in Series B Financing; Funds to Accelerate Commercialization of EarliPoint Evaluation and Further Product DevelopmentEarliTec Diagnostics raised $21.5 million in Series B financing led by Nexus NeuroTech Ventures and Venture Investors Health Fund. The funds will accelerate commercialization of EarliPoint Evaluation, a first-in-kind autism diagnostic tool for toddlers, and advance clinical research. Georgia Medicaid has included EarliPoint in its medical policy.Disability ScoopFDA Approves Device To Help Identify Autism EarlierThe FDA granted 510(k) clearance to EarliTec Diagnostics for its EarliPoint System, a prescription device to aid autism diagnosis in children ages 16 to 30 months. The device uses eye-tracking technology to analyze visual behavior, and the FDA determined it is substantially equivalent to the previously approved Cognoa device.Business Wire BlogEarliTec Diagnostics Receives FDA 510(k) Clearance for the EarliPoint Evaluation for Autism Spectrum DisorderEarliTec Diagnostics received FDA 510(k) clearance for its EarliPoint Evaluation for Autism Spectrum Disorder, the first objective tool for diagnosing ASD in children as young as 16 months. The clearance is based on two studies with over 500 participants, and the company plans to continue clinical research and deepen partnerships.WebrazziOtizmi teşhis etmeye odaklanan EarliTec Dx, 19,5 milyon dolar aldıEarliTec Dx, an Atlanta-based startup focused on diagnosing autism, raised $19.5 million in a round led by Bernie Marcus with Georgia Research Alliance. The funding will support its R&D, which analyzes eye movements and behavior to detect developmental disorders in children.